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Abstract
Genotype 4 Hepatitis C virus represents approximately 20% of global Hepatitis C virus infection and
is the source of a considerable burden to health-care providers across the globe. Many studies
reported that interferon reduces the risk of hepatocellular carcinoma in patients with chronic
hepatitis C.
Hereby, we are reporting two cases of hepatocellular carcinoma in Hepatitis C virus-genotype 4 after
complete viral eradication and in absence of cirrhosis. We aim to highlight the possible direct
oncogenic effect of Hepatitis C virus-genotype 4, particularly with concomitant bilharzial infection
and the importance of life-log follow up of these patients even in absence of cirrhosis.
Introduction
Preliminary evidence suggests that genotype 4 Hepatitis C
virus (HCV) infection may place patients at greater risk
for hepatocellular carcinoma (HCC) than other HCV
variants [1].
The precise mechanism by which HCV infection causes
HCC is not known. The development of cirrhosis is usually
the cause of HCC in HCV infection. It was reported that
IFN treatment prevents the development of HCC in
patients with HCV-related cirrhosis regardless the response
status [2]. However, the preventive effect seems to be
stronger among sustained responders [3]. Few reported
cases of HCC were described after HCV eradication, but
none in genotype 4. Most of reports suggested that old age,
presence of cirrhosis and genotype 1 had the high risk of
developing HCC after sustained response (SR) [4]. We are
describing for the first time 2 cases, middle aged of
genotype 4, who developed HCC after viral clearance in
spite of pre-treatment low viral load and absence of
cirrhosis.
We aim to highlight the possible direct oncogenic effect of
HCV-genotype 4 and the importance of life-log follow up
of these patients even in absence of cirrhosis. In addition,
we shall discuss the impact of concomitant schistosomal
co-infection on progression to HCC.
Case presentation
Case report 1
A 47-year-old, Egyptian, male patient, was diagnosed
to have post HCV chronic active hepatitis since 1995 and
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of blood transfusion, alcohol consumption or drug abuse.
In 2006, he was scheduled in Hamad Hospital, Qatar for
Pegylated-interferon (Peg-IFN) – Ribavirin therapy and
pre-treatment investigations showed positive PCR for
HCV-RNA with titer 328,000 IU/ml, genotype 4 and
liver biopsy was of grade I/IV stage II/IV (according to
Scheuer Score), minimal steatosis but no excess iron or
malignant changes. Liver function tests (LFT) showed
increased alanine amino-transferase (ALT) 107 U/L. He
has thrombocytopenia 150,000 × 10
3/ml. Sero-markers
for concomitant Hepatitis B (HBV) were negative.
Abdominal ultrasound scanning did not show focal lesion
and Alfa-fetoprotein (AFP) was 34 IU/ml. He was treated
between February 2006 and Feb 2007 with Peg-IFN 2a
180 ug weekly in combination with ribavirin 1000 mg
daily. Because of thrombocytopenia since second dose,
Peg-IFN2a was reduced to 135 ug till the end of treatment.
Viral clearance was detected since week 4. At the end of 48
weeks-treatment, PCR was negative for HCV-RNA, ALT 51
U/L, Platelet 150,000, and AFP 31.3 U/ml.
In march 27, 2008 the he presented with right hypocho-
drial pain and low grade fever. Computed tomography
(CT) abdomen showed an area of HCC within posterior
tsectoroftherightlobewithpredominantdiseasecentered
within segment VI and VII, evidence of tumor thrombus
within the portal vein. No lymph node involvement was
noted. The diagnosis was confirmed by liver biopsy. PCR
was still negative for HCV-RNA. Local treatment chemo-
embolization was performed on March 25, 2008, followed
by orthotopic liver transplantation in May 5, 2008.
Case report 2
A 48-year-old Egyptian male patient presented in 2000
with positive serology for HCV and high transaminases
ALT/AST 182/120 U/L, while albumin and bilirubin were
normal. He had history of bilharziasis treated with tartar
emetic during childhood and with praziquantel in 1991.
PCR was positive for HCV-RNA at a titer 104,000 IU/ml of
genotype 4. CBC was normal (Platelet 115 × 10^3/ul and
Hemoglobin 16.5 g/dl). Liver biopsy showed picture of
interface hepatitis, with fibrosis of Stage III/IV (according
to Scheuer Score), with no stainable iron, malignancy or
steatosis detected. AFP was 23.1 IU/ml. Serological
screening for concomitant HBV was negative. There was
no alteration in serum iron balance. There was no history
of alcohol consumption or drug abuse. He was treated
with Pegylated-IFN2a 180 ug weekly and Ribavirin
1200 mg daily for 48 weeks with complete sustained
response. He showed rapid virological response (RVR)
with viral clearance at week 4. Last dose was in February
2003. Follow up LFT showed biochemical response
(although it was high during treatment), normal blood
picture, normal thyroid function, normal coagulation
profile, and AFP of 20 IU/ml. Annual follow up showed
sustained virological response till May 2007. After 4 years
of sustained virologic response, the patient was referred to
a hospital and Ultrasound scanning revealed a hepatic
focal lesion, which was confirmed MRI, which also
showed a suprarenal focal lesion. Right hepatic lobe
focal lesion measured 11.8 × 11 cm. The mass was beyond
surgical resection and criteria for liver transplantation, so
the patient received local palliative treatment with chemo-
embolization. At that time AFP was 42 IU/ml. Follow up
after 6 sessions of local treatment showed minimal
decrease in the largest lesion and increase in necrotic
component with decreased in enhancement in all liver
lesions. AFP was 50 IU/ml. PCR for HCV is still negative
till now.
Discussion
Unlike HBV, HCV does not integrate into the host genome
[5]. Accordingly, the development of cirrhosis seems to be
the major risk factor for HCC in HCV infection. It is
reported that, viral clearance is associated with improve-
ment in liver histology, stabilization of liver disease, and
possibly, reduction in risk of HCC [6]. In our cases and
previous reports [7,8], the patients developed HCC in spite
of viral clearance, suggesting that HCV per se could have a
direct oncogenic effect. This may be attributed to genetic
mutation induced by HCV. Consistent differences in gene
expression patterns were recently reported in HCV-HCC
compared with early HCV cirrhosis, late HCV cirrhosis,
and normal controls [9]. Experimental observations
suggest that certain HCV genomic regions, such as Core
and non-structural protein-3 (NS3), might have oncogenic
properties [10]. Recent studies reported a relationship
between the presence of mutations within the IFN-
sensitive determining region (ISDR) and the development
of HCC. HCV-genotype 4 has heterogeneity within the
hypervariable region 1 and the NH2 region of the E2
protein. These indicate that HCV genotype 4 in Egypt is
extremely variable not only in terms of sequence, but also
in terms of functional and immunologic determinants
[11]. Genotype 4 infection may be considered a risk factor
for neu-oncoprotein over-expression and subsequent
development of HCC [12]. Also, HCV RNA was detected
in the serum, liver, and tumor tissues of patients with HCC
[13]. It is also worth mentioning that in Japan, the
development of HCC in patients without cirrhosis is
routinely reported, even with mild degrees of fibrosis [14].
Similarly, case 1 presents progression to HCC in a case of
minimal fibrosis, suggesting that progression to HCC may
occur in absence of cirrhosis and possibly providing
further evidence for the direct oncogenic effect of HCV.
IFN itself, through its growth-inhibitory effect, may delay
the growth of HCC [15]. Therefore, the actual mean time
for the tumor formation of HCC of 1 cm in diameter may
be longer than 6 years [16], and it is reasonable to consider
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up period after IFN therapy had already developed prior to
IFN therapy. So, the late appearance of HCC in our case
(more than 4 years) and previous cases (90 and
70 months) [7] may be attributed to the oncogenic effect
of HCV prior to eradication, providing another substantial
evidence.
The virological response persists over time and is
associated with a very low incidence of liver compli-
cations. Advanced age both at inclusion, or at infection,
viral genotype 1, low platelets, advanced histological
staging and possibly some specific HLA alleles [15-16], are
factors independently associated with a faster rate of
progression towards liver complications. In our cases, all
were middle aged and of genotype 4. From our cases and
others, viral load and genotype did not seem to influence
the progression to HCC. An important point which still
needs to be clarified is whether viral eradication tested in
our patients and others reflects a real clearance from
hepatic tissue? None of reported cases checked PCR in
hepatic tissues in spite of the fact that early report by Esaki
et al 2004, suggested that HCV-RNA was detected in liver
tissue in HCC patient with negative HCV serology [17].
Also, recent studies, have found trace HCV viral material in
liver tissue both among sustained responders and in
patients with chronic liver disease who were HCV RNA
negative, suggesting occult hepatitis C [18]. Within the
past few year, published reports have strongly proposed
the notion that HCV RNA may be expressed in liver and
extrahepatic reservoirs, in the absence of circulating
viremia, and that the virus may be active, and may
facilitated the development of HCC [19].
In our opinion, liver tissue HCV-RNA seems to be an
important tool in confirming viral clearance; however, the
idea of using an invasive technique to follow up a patient
who has presumably eradicated his virus might be not
easily accepted.
Our patients have concomitant bilharzial infestation.
Concurrent Schistomsoma mansoni infection may have an
important impact on the outcome of liver disease in
patients with HCV,with ahigher incidence of cirrhosis and
elevated risk for hepatocellular carcinoma seen in HCV
genotype 4 and schistosomiasis coinfected patients than in
those with HCV alone [20], histology scores for grade
(total inflammatory score) and stage (fibrosis/cirrhosis
score) were significantly higher in coinfected individuals.
We can conclude that HCC may developed in HCV
genotype 4 after viral clearance because direct oncogenic
effect through genetic mutation which may take place
before starting interferon therapy, extrahepatic and possi-
ble occult HCV, and concomitant bilharzial infection. So,
we recommend life-long follow up screening with ultra-
sound and alpha-fetoprotein after HCV clearance in
genotype 4, should be considered for all cases, regardless
the stage of fibrosis or presence of concomitant factors for
progression to HCC.
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